Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS study^*

References

• Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011–53
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10–7
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens 1995;9:791–6
   Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, Dahlof B, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–62
   PubMed Web of Science ®Google Scholar
• The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, Brunner HR, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049–51
   PubMed Web of Science ®Google Scholar
• Dahlof B, Hansson L, Lindholm LH, Schersten B, et al. Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin Exp Hypertens 1993;15:925–39
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Williams D. Lessons from combination therapy in Veterans Affairs Studies. Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. Am J Hypertens 1996;9:187S–91
   Google Scholar
• Cushman WC, Ford CE, Cutler JA, Margolis KL, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393–404
   PubMedGoogle Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Julius S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805–16
   Google Scholar
• Preterax® 2 mg/0.625 mg tablet. European summary of product characteristics. Servier International, Neuilly sur Seine, France, 2003
   Google Scholar
• Mogensen CE, Viberti G, Halimi S, Ritz E, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003;41:1063–71
   PubMed Web of Science ®Google Scholar
• Dahlof B, Gosse P, Gueret P, Dubourg O, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063–70
   PubMed Web of Science ®Google Scholar
• Mourad JJ, Waeber B, Zannad F, Laville M, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004;22:2379–86
   PubMed Web of Science ®Google Scholar
• Mallion JM, Chamontin B, Asmar R, De Leeuw PW, et al. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am J Hypertens 2004;17:245–51
   Google Scholar
• Castaigne A, Chalmers J, Morgan T, Chastang C, et al. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/ indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension. Clin Exp Hypertens 1999;21: 1097–110
   Google Scholar
• Chanudet X, De Champvallins M. Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. Int J Clin Pract 2001;55:233–9
   PubMed Web of Science ®Google Scholar
• Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000;18:327–37
   PubMed Web of Science ®Google Scholar
• Asmar RG, London GM, O’Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hyper-tensive patient: a comparison with atenolol. Hypertension 2001;38:922–6
   Google Scholar
• Laurent S. Clinical benefit of very-low-dose perindoprilindapamide combination in hypertension. J Hypertens Suppl 2001;19:S9–14
   PubMedGoogle Scholar
• de Luca N, Mallion JM, O’Rourke MF, O’Brien E, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004;17:660–7
   Google Scholar
• Bi Preterax® 4 mg/1.5 mg tablet. European summary of product characteristics. Servier International, Neuilly sur Seine, France, 2002
   Google Scholar
• Waeber B. Very-low-dose combination: a first-line choice for the treatment of hypertension? J Hypertens Suppl 2003;21:S3–10
   PubMedGoogle Scholar
• Waeber B. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. Am J Hypertens [in press]
   Google Scholar
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413–46
   PubMed Web of Science ®Google Scholar
• Chalmers J. Trials on blood pressure-lowering and secondary stroke prevention. Am J Cardiol 2003;91:3G–8
   Google Scholar
• PROGRESS Collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358: 1033–41
   Google Scholar
• Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. PROGRESS Collaborative Group. Eur Heart J 2003;24:475–84
   PubMed Web of Science ®Google Scholar
• The CAFÉ Investigators. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation Study: The (CAFÉ) Study. Circulation 2006;113:1213–25
   Google Scholar
• Safar ME, Vaisse B, Blacher J, Rudnichi A, et al. Pulse pressure monitoring of open antihypertensive therapy. Am J Hypertens 2004;17:1088–94
   PubMed Web of Science ®Google Scholar